Security key
114082209
Ernexa Therapeutics Inc. - Common Stock (ERNA)
CUSIP: 114082209
Q4 2022 13F Holders as of 31 Dec 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 1,166,181
- Total 13F shares
- 329,815
- Share change
- +268,626
- Total reported value
- $1,192,085
- Price per share
- $3.22
- Number of holders
- 18
- Value change
- +$995,056
- Number of buys
- 17
Report period
Q4 2022
Institutions
18
Top holders
10
ERNA full security history
Newer quarter: Q1 2023
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 114082209
Recent filing periods:
Top shareholders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| George P. Denny III |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
457,442
|
$1,134,456 | — | 02 Dec 2022 | |
| John D. Halpern |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
1,123,006
mixed-class rows
|
$1,118,891 | — | 02 Dec 2022 | |
| Nicholas J. Singer |
3/4/5
|
Director |
—
mixed-class rows
|
954,608
mixed-class rows
|
$962,330 | — | 02 Dec 2022 | |
| Roger Sidhu |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
80,650
mixed-class rows
|
$200,012 | — | 20 Sep 2022 | |
| Kevin Damour |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
64,213
mixed-class rows
|
$159,248 | — | 28 Jun 2022 | |
| Andrew C. Jackson |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
664,800
|
— | — | 03 Jun 2022 | |
| Howard J. Federoff |
3/4/5
|
CEO & President, Director |
—
class O/S missing
|
413,700
|
— | — | 11 Mar 2022 | |
| Gregory Fiore |
3/4/5
|
Director |
—
class O/S missing
|
165,800
|
— | — | 01 Aug 2022 | |
| Jay Sial |
3/4/5
|
Chief Administration Officer |
—
class O/S missing
|
117,200
|
— | — | 11 Mar 2022 | |
| Dennis Langer |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 | |
| Erich Mohr |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 | |
| Erin S. Enright |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 14 Jan 2022 | |
| Heather B. Redman |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 14 Jan 2022 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 |
Institutional Holders of Ernexa Therapeutics Inc. - Common Stock (ERNA) as of Q4 2022
As of 31 Dec 2022,
Ernexa Therapeutics Inc. - Common Stock (ERNA) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
329,815 shares.
The largest 10 holders included
Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, CI Private Wealth, LLC, VANGUARD GROUP INC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BALDWIN BROTHERS LLC/MA, MORGAN STANLEY, and CREDIT SUISSE AG/.
This page lists
18
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q1 2025 Across Filers
Q1 2025 holders
26
Q4 2022 holders
18
Holder diff
-8
| Investor | Q1 2025 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.